八基因尿液RNA检测无创诊断上尿路尿路上皮癌的大规模前瞻性验证研究
研究前瞻性收集五个临床中心2022年10月至2023年8月间61例上尿路尿路上皮癌(UTUC)患者和99例无尿路上皮癌对照者的尿液,用八基因尿液RNA检测分析。该检测在单中心测试队列(n=93)AUC为0.901,在多中心临床验证队列(n=66)AUC为0.926,合并验证队列灵敏度90.16%、特异度88.89%、总准确率89.38%。
要点
- 八基因尿液RNA检测在合并验证队列灵敏度90.16%、特异度88.89%、总准确率89.38%。
- 11例低级别UTUC患者中该检测准确率达100%。
- 作者认为该检测可用于识别UTUC患者,减少对输尿管镜和盲目手术的依赖。
核心结论
- 八基因尿液RNA检测能以高灵敏度和特异度准确区分UTUC与其他泌尿系统疾病。
- 作者认为该检测在临床实践中可用于有效识别UTUC患者,从而减少对输尿管镜和盲目手术的依赖。
研究设计与样本
- 前瞻性收集五个临床中心2022年10月至2023年8月间61例UTUC患者和99例无尿路上皮癌对照者的尿液,采集于任何侵入性检查(膀胱镜或输尿管镜)或治疗之前。
- 所有样本用由CA9、CCL18、ERBB2、IGF2、MMP12、PPP1R14D、SGK2和SWINGN八个基因组成的尿液RNA检测分析,结果以每位参与者的风险评分表示并据此分为低危或高危组。
- UTUC诊断主要基于术前影像学检查标准并由术后病理结果确认,采用递归特征消除和支持向量机算法、χ2检验和Student t检验进行分析。
主要发现
- 八基因尿液检测在单中心测试队列(n=93)的AUC为0.901,在多中心临床验证队列(n=66)的AUC为0.926。
- 在合并验证队列中,八基因尿液检测灵敏度为90.16%、特异度为88.89%、总准确率为89.38%。
- 在11例低级别UTUC患者中该检测准确率达到100%。
- 多基因RNA尿液检测得出的风险评分在UTUC患者与相应对照者之间差异显著。
临床怎么用
- 作者认为该八基因尿液RNA检测在临床实践中可用于有效识别UTUC患者,从而减少对输尿管镜和盲目手术的依赖。
局限性
- 本研究仅在单一术前时间点采集UTUC患者尿液,未在监测人群中对UTUC病理过程进行连续检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current approaches for diagnosis and monitoring of upper tract urothelial carcinoma (UTUC) are often invasive, costly, and not efficient for early-stage and low-grade tumors. OBJECTIVE: To validate a noninvasive urine-based RNA test for accurate UTUC diagnosis. DESIGN, SETTING, AND PARTICIPANTS: Urine samples were prospectively collected from 61 patients with UTUC and 99 controls without urothelial carcinomas, in five clinical centers between October 2022 and August 2023 prior to any invasive test (cystoscope or ureteroscope) or treatment. All samples were analyzed with a urine-based RNA test composed of eight genes (CA9, CCL18, ERBB2, IGF2, MMP12, PPP1R14D, SGK2, and SWINGN). The test results were presented with a risk score for each participant, which was applied to categorize patients into low- or high-risk groups. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The diagnosis of UTUC was based mainly on preoperative radiological examination criteria and confirmed by postoperative pathological results. The recursive feature elimination and support vector machine algorithms, χ2, and Student t test were used. RESULTS AND LIMITATIONS: The eight-gene urine test accurately detected UTUC patients and controls with an area under the curve (AUC) of 0.901 in a single-center testing cohort (n = 93) and an AUC of 0.926 in a multicenter clinical validation cohort (n = 66). In the merged validation cohort, the eight-gene urine test achieved high sensitivity of 90.16%, specificity of 88.89%, and overall accuracy of 89.38%. Remarkably, excellent performance was achieved in 11 low-grade UTUC patients with accuracy of 100%. However, this study collected the urine of UTUC patients only at a single preoperative time point and did not perform continuous tests during the pathological process of UTUC in the surveillance population. CONCLUSIONS: Our results demonstrated that the eight-gene urine test can differentiate accurately between UTUC and other urological diseases with high sensitivity and specificity. In clinical practice, it may be used for identifying UTUC patients effectively, leading to reduced reliance on ureteroscopy and blind surgery. PATIENT SUMMARY: In this study, we investigated a multiplex RNA urine test for noninvasive upper tract urothelial carcinoma (UTUC) diagnosis before treatment. We found that the risk scores derived from the multiplex RNA urine test differed significantly between UTUC patients and corresponding controls.
引用
- Zhang H, Xu Y, Wang K, et al. Large-scale Prospective Validation Study of a Multiplex RNA Urine Test for Noninvasive Detection of Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2024. PMID: 38523018. doi:10.1016/j.euo.2024.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。